November 2003
Worldwide Biotech;Nov2003, Vol. 15 Issue 11, p8
Trade Publication
Reports on the entry of Chromos Molecular Systems and Xencor into a non-exclusive research license agreement to develop cell lines that express Xencor's monoclonal antibodies as of November 2003.


Related Articles

  • OTHER NEWS TO NOTE.  // BioWorld Today;11/16/2007, Vol. 18 Issue 224, p2 

    This section offers news briefs on the pharmaceutical and biotechnology industries. Israel-based BioLineRx Ltd. signed a license agreement with Yissum and Hadasit for the development and commercialization of a cancer drug candidate. Chromos Molecular Systems Inc. of Burnaby, British Columbia...

  • Germline transmission of artificial chromosome. Dove, Alan // Nature Biotechnology;Dec99, Vol. 17 Issue 12, p1149 

    Focuses on the release of a satellite DNA-based artificial chromosome (SAT-DAC) by a biotechnology company Chromos Molecular Systems Inc. Use of the chromosome in the insertion of any gene into mammalian cells without the risk of disrupting other genes; Plans of the company regarding use of the...

  • OTHER NEWS TO NOTE.  // BioWorld Today;4/5/2007, Vol. 18 Issue 66, p3 

    The article presents news briefs on biotechnology industry in the U.S. The holders of Chromos Molecular Systems Incorporated's convertible, secured bridge loan have demanded repayment of the principal and interest. CytoGenix Inc. has completed a pilot study for its synDNA vaccine for human...

  • Pass it on. Coghlan, Andy // New Scientist;07/08/2000, Vol. 167 Issue 2246, p7 

    Describes how artificial chromosomes can pass from one generation to the next. Description of an experiment by Deborah Co of Chromos Molecular Systems in Burnaby, British Columbia to implant altered chromosomes into mice; Outlook for future experiments on protein-producing genes; Chromosomes...

  • Financings Roundup.  // BioWorld Today;3/24/2008, Vol. 19 Issue 57, p3 

    The article reports on a secured, convertible debenture agreement entered into by Chromos Molecular Systems Inc. The Burnaby, British Columbia-based company will get $400,000 from the agreement which will be used for expenses related to delinquent continuous disclosure documents and assets. On...

  • We have the power. Coghlan, Andy // New Scientist;10/23/99, Vol. 164 Issue 2209, p4 

    Discusses legal and moral aspects of human germline gene therapy and how future generations might be impacted. Details of a study on mice by Chromos Molecular Systems of Burnaby, British Columbia; Mistakes in gene therapy that prohibit its use in humans; How gene therapy could help treat and...

  • CHROMOSOME CURE. Jonietz, Erika // Technology Review;Apr2003, Vol. 106 Issue 3, p29 

    Reports on the tests made by Athersys and Chromos Molecular Systems on the use of artificial chromosomes as a safe and effective way to introduce therapeutic genes into patients suffering from genetic disorders. Comparison between the use of artificial chromosome and conventional gene therapy;...

  • Multiple Sclerosis Update.  // PharmaWatch: CNS;August 2005, Vol. 4 Issue 8, p6 

    The article presents information about recent developments related to multiple sclerosis. Biogen Idec Inc. has identified a molecule in the central nervous system that may play a pivotal role in nerve repair and regeneration which could be used in the treatment of multiple sclerosis. Chromos...

  • MGI Pharma to acquire Guilford Pharmaceuticals.  // PharmaWatch: Biotechnology;Sep2005, Vol. 4 Issue 9, p19 

    The article reports that Chromos Molecular Systems Inc. has entered into a letter of intent to acquire Targeted Molecules Corp. (TMC), a privately held San Diego based biotechnology company focused on the Research & Development of two antibody product candidates in multiple sclerosis and acute...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics